Cross-kingdom botanical intelligence platform. Predicts therapeutic compounds across four biological kingdoms — cannabis, marine polysaccharides, fungi, and plant polysaccharides — before physical testing.
NeuroBotanica™ combines a patented workflow integration methodology with proprietary analytical engines to deliver pharmaceutical-grade therapeutic prediction at accessible price points.
The platform's proprietary AI prediction model predicts molecular interactions across compound classes. The dimeric prediction framework generates novel molecular combinations with formation probability, synergy scores, and condition-specific therapeutic potential.
Cannabis is the entry point — not the ceiling. Testing labs are the wedge: binding a verified clinical-inference layer to characterization work labs already run is the first commercial vertical in a 7-phase expansion reaching pharmaceutical R&D, clinical medicine, and cultivation.
Binds a verified clinical-inference layer to the COA a lab already runs. No new assay, no retail integration — the lab keeps its own brand. Turns existing compliance data into a defensible, client-facing intelligence product.
Our proprietary AI prediction model predicts cross-kingdom molecular interactions. Not a lookup table — a generative model.
Polysaccharide-cannabinoid receptor interaction modeling. Marine, fungal, and plant polysaccharides mapped against cannabinoid and terpene classes.
Every recommendation ranked by evidence quality. Meta-analysis → RCT → cohort → in vitro → traditional use. Fully auditable at every step.
The traditional knowledge integration layer integrates FPIC-validated traditional knowledge. VeriTrad™-verified, consent-logged, attribution-tracked.
The regulatory pathway mapping layer maps compounds to FDA and DSHEA pathways. GRAS notifications, NDI submissions, clinical trial readiness built in.
Access to 565+ study database, proprietary AI predictions, and cross-kingdom synergy models. API access for academic and industry researchers.
Request AccessBind a verified clinical-inference layer to the COA you already run. A defensible, client-facing intelligence product on top of your existing characterization workflow — no new assay required.
Partner as a LabClinical protocols, patient digital twins, neuropsychiatric therapeutics. Clinical and neuropsychiatric protocols. 3,000+ target US facilities.
Learn MoreWeb-based recommendation system. Evidence-based guidance for dispensary staff and patients.
Partner With UsTesting labs and cultivators: bind a verified clinical-inference layer to your existing COA workflow. Researchers: request API access to the 565+ study database.